New Generation of Biologics
Cenik najema prostorov FE

Programme Coordinator:

CO BIK - Centre of Excellence for Biosensors, Instrumentation and Process Control



National Institute of Chemistry, Lek d.d., Metronik d.o.o., National Institute of Biology, BIA d.o.o., UL Faculty of Electrical Engineering, UL Faculty of Computer and Information Science, Faculty of Chemistry and Chemical Technology, Instrumentation Technologies d.d.


Project value: 8.810.160,00 EUR


Amount of co-financing: 5.972.371,63 EUR


Priority area: Health - Medicine


Period of the programme: 14.07.2016 - 30.06.2020


Description of the programme:

The main goal of BioPharm.Si programme, involving high tech and biotech Slovenian companies and excellent research institutions, is development of continuous manufacturing processes and innovative devices and services that will facilitate transition from batch to fully continuous manufacturing of biologics.

Manufacturing of biologics and vaccines in the form of proteins, DNA, and viruses is operationally and technologically challenging. Producing large molecules reproducibly on an industrial scale requires manufacturing capabilities with a previously unknown sophistication. Conventionally, the biologics manufacturing process is done in batch mode, where each production step starts and ends independently from the previous and following step. Therefore, the goal of biopharmaceutical industry is in the transition from batch processing to fully continuous processing, mainly to increase productivity, maximize flexibility, simplify scale-up and process transfers, increase robustness, and minimize cost of goods while still maintaining operational excellence.


The programme focus is on seven key areas: LMSE staff are involved in RDP2 – Monitoring Quality of Biologics.


The expected results of the programme:

-     25 innovations and 6 patents,

-     10 % increase of private investments in R&D,

-     4 prototypes, 5 new methods, and 4 services for the global market,

-     Developing technologies, services and products for the global market,

-     At least one newly established company is foreseen that will pick up some of these technologies, develop hi-tech products and enter the global market,

-     An 8% increase in the added value of companies per employee by 2020 and an additional 5% by 2023,

-     Employment of at least 26 new researchers and engineers,

-     At least 9 collaboration projects between industry and academia.


The investment is co-financed by the Republic of Slovenia and the European Union from the European Regional Development Fund.